Table 4a Mean (s.d.) pharmacokinetic parameters of total and unbound cisplatin, with or without tipifarnib (100–300 mg)

From: Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours

Variable

Units

Gem/cis (s.d.) n =24

gem/cis+tipifarnib (s.d.) n =30

P -value a

Total cisplatin

 Median tmax

Hours

3.19

3.28

–

 Cmaxb

μg ml−1

4.72 (1.68)

4.29 (0.78)

0.124c

 AUC0-23b

h μg ml−1

63.0 (8.93)

61.6 (9.78)d

0.575c

 t1/2

Hours

40.6 (13.2)e

46.1 (18.4)c

—

Unbound cisplatin

 Median tmax

Hours

3.03

3.02

—

 Cmaxb

μg ml−1

1.91 (1.77)

1.59 (0.24)

0.898c

 AUC0-23b

h μg ml−1

6.84 (3.06)

5.80 (1.93)f

0.272g

 t1/2

Hours

9.01 (8.78)h

6.65 (18.2)i

—

Pt-AG

 AUA0-23b

fmol h μg−1

2.78j

2.66g

0.769k

Pt-GG

 AUA0-23b

fmol h μg−1

16.70g

18.52g

0.715k

  1. aTwo-sided P-value for testing a difference between the two treatments. Only data from patients who completed the study were included.
  2. bParameter values adjusted to 75 mg m−2 dose of cisplatin.
  3. cn=24.
  4. dn=29.
  5. en=17.
  6. fn=28.
  7. gn=23.
  8. hn=12.
  9. in=16.
  10. jn=22.
  11. kn=15.
  12. Gem=gemcitabine; cis=cisplatin.
Back to article page